enzh-CNfrdeitjakorues
Find out all about Recce

About Recce Pharmaceuticals

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is pioneering the development and commercialisation of a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.

Latest Announcements
View Archive
RECCE® 327's Unique and Multi-layered Mechanism of Action

There have been no new classes of antibiotics on the market for over 30 years - The need for new types of antibiotics is urgent as the number of drug resistant and multi-drug resistant bacterial infections continues to grow.

Recce is tackling this challenge head on through its new class of synthetic anti-infectives that have been shown to be highly effective against the hyper-cellular mutation of a wide range of Gram-positive and Gram-negative bacteria, including drug resistant forms.

What makes Recce anti-infectives so promising, is their unique and universal mechanism of action:

Studies indicate Recce’s compounds rapidly and irreversibly shut down bacterial cellular energy ATP production, disrupting important functions within the bacteria, leading to

  • A reduction in protein synthesis
  • Depolarization of cellular membranes
  • And in higher concentrations - Cell lysis

This multi-layered mechanism of action uniquely allows it to kill bacteria and keep on killing with repeated use, a challenge of all existing antibiotics.

As one of the most promising developments in the fight against drug resistant bacteria, Recce’s compounds are undergoing pivotal clinical trials for a range of life-threatening diseases. To find out more on RECCE® 327 and our other synthetic anti-infectives, visit recce.com.au.

Learn More

Follow the progress of our unique Australian innovation

Contact Us Today

Sign up for news and updates

Receive news and information direct to your inbox.